Semaglutide (administered by PDS290 pen-injector)

DRUG3 trials

Sponsors

Novo Nordisk A/S, Prof. Dr. Martin Wabitsch, Washington University School of Medicine

Conditions

Chronic Lower Back PainLower Back PainMonogenic ObesityObesityObesity (BMI>30)Overweightglp1 Agonist

Phase 1

A Research Study to Compare Two Different Forms of Once-weekly Semaglutide in Two Different Injection Pens

CompletedNCT04238962

Novo Nordisk A/SObesity, Overweight

Start: 2020-02-03End: 2020-10-20Updated: 2020-11-20

Phase 2

Semaglutide for Low Back Pain

Not yet recruitingNCT07731256

Washington University School of MedicineChronic Lower Back Pain, glp1 Agonist, Lower Back Pain +1

Start: 2027-02-01End: 2031-09-01Target: 250Updated: 2026-07-28

Unknown Phase

Efficacy of Semaglutide s.c. Once-weekly on Weight Loss and Management in Adolescents With Monogenic Obesity in Clinical Practice

RecruitingNCT07302802

Prof. Dr. Martin WabitschMonogenic Obesity

Start: 2025-12-01End: 2028-12-31Target: 70Updated: 2026-01-08